Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 17 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release detailing two recent approvals from the USFDA. The approvals are for Valbenazine Capsules and Roflumilast Tablets, both intended for specific medical treatments. Valbenazine is indicated for tardive dyskinesia, while Roflumilast is for reducing COPD exacerbations. Both drugs will be manufactured at the company's facility in Ahmedabad SEZ, India.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange about press release dated 17-Oct-2022 titled 1. Zydus receives tentative approval from the USFDA for Valbenazine Capsules and 2. Zydus receives tentative approval from the USFDA for Roflumilast Tablets

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases